Company Overview
Founded in 2022, StellarCell BioMedicine Inc. is rooted in the field of regenerative medicine, specializing in the research, development and application of cell therapy technologies. We possess Taiwan’s largest intellectual property database of clinical data in cell therapy. This is not only our core competitive advantage but also a key asset that drives the development of the entire industry.
Development strategy and future vision
- Market and product development: Continue promoting exosome-based formulations in Taiwan’s aesthetic medicine and regenerative medicine markets, expanding the scope of clinical applications.
- Operations and data optimization: Strengthen the production supply chain to enhance efficiency and quality, while continuing to accumulate clinical data intellectual property as a foundation for market expansion.
- Innovation and application expansion: Continue investing in cutting-edge technologies, driving clinical research and new drug applications for novel protein drugs and enhancing competitive advantages.
- Globalization strategy: Actively pursue international collaborations to promote the popularization of regenerative medicine and establish a prominent position in this rapidly developing field through innovative technologies and a professional team.
Key areas of product development
Exosome-based formulations
- For indications including degenerative arthritis, Parkinson’s disease, aging and dry eye syndrome
- Research in tissue regeneration applications
Proprietary protein drugs
- Development of new drug, NEGF (BB-101)
- Currently in Phase II clinical trials, focusing on post-laser surgery wound healing
Regenerative medicine-based post-aesthetic procedure skincare products
- Combining clinical data to develop highly effective products in regenerative aesthetic medicine
- R&D of USC-E product series
Technical advantages in exosome-related products
Fully automated production line
- 3A-GTP fully automated manufacturing process
- Digital real-time monitoring ensures stability in quality and maximized yield
- GTP-compliant exosome manufacturing ensures maximum safety
High concentration, purity and quality
- Exosome concentration: 2000 × 108 particles/ml
- Exosome purity: 50–150nm >90%
- Exosome Quality: Produced using a fully automated cell culture tower certified as a Class II medical device by the Taiwan Ministry of Health and Welfare (TFDA)
Advanced isolation and purification technologies
- Proprietary methods for exosome isolation and purification
- Ensures high bioactivity and low immunogenicity
Clinical collaborations and data accumulation
- We collaborate with top medical institutions such as the Department of Dermatology at Shuang Ho Hospital, Ministry of Health and Welfare and the Department of Neurosurgery at Taichung Veterans General Hospital.
- We continuously accumulate clinical data from leading institutions of aesthetic medicine to build an expansive clinical data intellectual property database.
- We promote the practical application of cell therapy technologies across diverse medical fields.